Patents Assigned to ADAGENE PTE. LTD.
  • COMBINATION THERAPY COMPRISING ANTI-CD137 ANTIBODIES
    Publication number: 20230242663
    Abstract: The present application provides compositions and methods for treating cancers in a subject using an anti-CD137 antibody and an agent that induces expression of CD137 on an immune cell and/or induces expression of CD137L on a cancer cell of the subject. In some embodiments, the agent is a cytokine such as IL-2. In some embodiments, the agent is a histone deacetylase (HDAC) inhibitor. In some embodiments, the agent is a DNA-damaging agent.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 3, 2023
    Applicant: Adagene PTE. LTD.
    Inventors: Peter Peizhi LUO, Guizhong LIU, Aaron NGUYEN
  • ANTI-CD137L ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20220089757
    Abstract: Provided herein are antibodies that bind to an intracellular/transmembrane portion of human CD137L, as well as methods relating to the use of these antibodies for detecting CD137L expression in a sample and the detection of CD137L expression as a biomaker for cancer treatment.
    Type: Application
    Filed: June 4, 2020
    Publication date: March 24, 2022
    Applicant: ADAGENE PTE. LTD.
    Inventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU